Common Contracts
3 similar Sales Agreement contracts by AEON Biopharma, Inc., Sagimet Biosciences Inc., Zura Bio LTD
ZURA BIO LIMITED US$125,000,000 CLASS A ORDINARY SHARES SALES AGREEMENTSales Agreement • September 3rd, 2024 • Zura Bio LTD • Biological products, (no disgnostic substances) • New York
Zura Bio Limited, a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
AEON BIOPHARMA, INC. Shares of Class A Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • August 15th, 2024 • AEON Biopharma, Inc. • Pharmaceutical preparations • New York
On the date hereof, AEON Biopharma, Inc., a Delaware corporation (the “Company”), has filed or will file with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on Form S-3 that contains a base prospectus as well as a sales agreement prospectus covering the offering, issuance and sale by the Company of shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50,000,000. The parties agree to be legally bound by the terms of this Agreement effective immediately upon such registration statement being declared effective by the Commission.
Sagimet Biosciences Inc. Shares of Series A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 15th, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations • New York
Sagimet Biosciences Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
